Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt Sells 12,075 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 12,075 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $7.32, for a total value of $88,389.00. Following the completion of the transaction, the chief executive officer now directly owns 819,758 shares of the company’s stock, valued at $6,000,628.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Zhenya Lindgardt also recently made the following trade(s):

• On Tuesday, September 10th, Zhenya Lindgardt sold 25,085 shares of Sera Prognostics stock. The shares were sold at an average price of $7.57, for a total transaction of $189,893.45.

Sera Prognostics Price Performance

Shares of NASDAQ SERA opened at $7.24 on Wednesday. The company’s fifty day moving average price is $7.41 and its 200 day moving average price is $7.65. Sera Prognostics, Inc. has a 1 year low of $1.65 and a 1 year high of $12.35.

Sera Prognostics (NASDAQ:SERA) last posted its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same quarter in the prior year, the firm posted ($0.23) earnings per share. As a group, analysts anticipate that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Trading of Sera Prognostics

Institutional investors have recently bought and sold shares of the business. Quest Partners LLC raised its stake in shares of Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after buying an additional 5,415 shares during the period. Prime Capital Investment Advisors LLC purchased a new stake in Sera Prognostics in the 3rd quarter worth $104,000. SG Americas Securities LLC acquired a new position in Sera Prognostics during the third quarter worth $78,000. The Manufacturers Life Insurance Company purchased a new position in Sera Prognostics during the second quarter valued at $68,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Sera Prognostics during the second quarter worth about $162,000. 54.64% of the stock is owned by institutional investors and hedge funds.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.